148 related articles for article (PubMed ID: 20140937)
1. Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3.
Li WW; Chen JJ; Zheng RL; Zhang WQ; Cao ZX; Yang LL; Qing XY; Zhou LX; Yang L; Yu LD; Chen LJ; Wei YQ; Yang SY
ChemMedChem; 2010 Apr; 5(4):513-6. PubMed ID: 20140937
[No Abstract] [Full Text] [Related]
2. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of quinazolines as tyrosine kinase inhibitors.
Srivastava SK; Kumar V; Agarwal SK; Mukherjee R; Burman AC
Anticancer Agents Med Chem; 2009 Mar; 9(3):246-75. PubMed ID: 19275520
[TBL] [Abstract][Full Text] [Related]
4. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
[TBL] [Abstract][Full Text] [Related]
5. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
[TBL] [Abstract][Full Text] [Related]
6. Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3.
Patch RJ; Baumann CA; Liu J; Gibbs AC; Ott H; Lattanze J; Player MR
Bioorg Med Chem Lett; 2006 Jun; 16(12):3282-6. PubMed ID: 16580199
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 5-methyl-
Im D; Moon H; Kim J; Oh Y; Jang M; Hah JM
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1110-1115. PubMed ID: 32338093
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
El-Deeb IM; Park BS; Jung SJ; Yoo KH; Oh CH; Cho SJ; Han DK; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Oct; 19(19):5622-6. PubMed ID: 19700314
[TBL] [Abstract][Full Text] [Related]
9. Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors.
Yang SH; Khadka DB; Cho SH; Ju HK; Lee KY; Han HJ; Lee KT; Cho WJ
Bioorg Med Chem; 2011 Jan; 19(2):968-77. PubMed ID: 21185195
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
[TBL] [Abstract][Full Text] [Related]
11. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors.
Kitano Y; Suzuki T; Kawahara E; Yamazaki T
Bioorg Med Chem Lett; 2007 Nov; 17(21):5863-7. PubMed ID: 17869510
[TBL] [Abstract][Full Text] [Related]
15. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
[TBL] [Abstract][Full Text] [Related]
16. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors.
Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N
Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388
[TBL] [Abstract][Full Text] [Related]
17. Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
Wenglowsky S; Ren L; Grina J; Hansen JD; Laird ER; Moreno D; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Sturgis HL; Voegtli WC; Vigers G; Willis B; Mathieu S; Rudolph J
Bioorg Med Chem Lett; 2014 Apr; 24(8):1923-7. PubMed ID: 24675381
[TBL] [Abstract][Full Text] [Related]
18. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
Hsu YC; Coumar MS; Wang WC; Shiao HY; Ke YY; Lin WH; Kuo CC; Chang CW; Kuo FM; Chen PY; Wang SY; Li AS; Chen CH; Kuo PC; Chen CP; Wu MH; Huang CL; Yen KJ; Chang YI; Hsu JT; Chen CT; Yeh TK; Song JS; Shih C; Hsieh HP
Oncotarget; 2016 Dec; 7(52):86239-86256. PubMed ID: 27863392
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity.
Li HQ; Li DD; Lu X; Xu YY; Zhu HL
Bioorg Med Chem; 2012 Jan; 20(1):317-23. PubMed ID: 22112541
[TBL] [Abstract][Full Text] [Related]
20. Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents.
Furet P; Bold G; Meyer T; Roesel J; Guagnano V
J Med Chem; 2006 Jul; 49(15):4451-4. PubMed ID: 16854049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
